Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Bal Pharma has reported results for first quarter ended June 30, 2021.
The company has reported 30.93% rise in its net profit at Rs 2.15 crore for the quarter under review as compared to net profit of Rs 1.64 crore for the same quarter in the previous year. Total income of the company increased by 35.40% at Rs 71.14 crore for Q1FY22 as compared Rs 52.54 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported around 4-fold jump in its net profit attributable to equity holdars of the parent company at Rs 1.62 crore for the quarter under review as compared to net profit of Rs 0.42 crore for the same quarter in the previous year. Total income of the company increased by 35.72% at Rs 70.96 crore for Q1FY22 as compared Rs 52.29 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |